ミズーリ州におけるCOPDの臨床試験
ミズーリ州内の拠点で、COPDに関する7件の研究が参加者を募集しています。
ミズーリ州内の都市
公式研究テキスト（英語）
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- University of Missouri Health Care - Children's Hospital- Site Number : 8400150, Columbia
- Hannibal Regional Healthcare System- Site Number : 8400035, Hannibal
- Washington University- Site Number : 8400144, St Louis
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/10/01更新 · NCT07190222Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD
- Midwest Chest Consultants, P.C., Saint Charles
被験者募集中第4相
60歳以上 · 全性別 · 2026/09/14更新 · NCT07816835A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Chesterfield
- Research Site, Hannibal
- Research Site, St Louis
- 他1件
被験者募集中第2相
40歳以上 · 全性別 · 2026/09/09更新 · NCT07082738A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Hannibal
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, St Louis
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Washington University School of Medicine, St Louis
- Barnes-Jewish Hospital Investigational Drug Service, St Louis
- Barnes-Jewish Hospital, St Louis
- 他2件
被験者募集中第2/3相
35歳〜80歳 · 全性別 · 2026/08/31更新 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, St Louis
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/08/26更新 · NCT06283966ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。